newsfilter
← Latest News
Business Wire·

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a